Regeneron Pharmaceuticals Inc $ 620.21 -1 (-0.16%)
Warning! GuruFocus has detected 1 Severe warning sign with REGN. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Regeneron Pharmaceuticals Inc () from 1991 to Aug 07 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Regeneron Pharmaceuticals stock (REGN) PE ratio as of Aug 07 2020 is 23.99. More Details
Regeneron Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 1991. Start your Free Trial
Regeneron Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:VRTX NAS:SGEN NAS:MRNA NAS:ALXN NAS:INCY NAS:BMRN NAS:ALNY NAS:SRPT NAS:NBIX NAS:BNTX OCSE:NOVO B ASX:CSL XKRX:207940 XKRX:068270 HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122 XBRU:UCB XAMS:GLPG
Traded in other countries REGN.Austria REGN34.Brazil RGO.Germany REGN.Mexico REGN.Switzerland 0R2M.UK REGN.USA
Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.